Archive · 20 Jul 2026
Tatva Chintan Pharma Shares Surge 18%
Tatva Chintan Pharma Chem's stock price jumped by 18% on July 20, 2024, reaching ₹1,685.10.
This surge was driven by the company's strong financial performance in the first quarter of the fiscal year 2027.
The company's revenue grew by 42% compared to the same quarter last year, while its operating profit (EBITDA) increased by 88%.
Net profit more than doubled, rising by 142% year-on-year.
Investors were optimistic about these results, pushing the stock to a new 52-week high of ₹1,713.70.
The company's market capitalization is now near ₹3,940 crore, with a price-to-earnings ratio of 93.72.
While investors are bullish, analysts caution about the high valuation and potential market risks.
Tatva Chintan Pharma Chem's stock surged 18% to ₹1,685.10 on July 20, 2024.
Revenue grew 42% year-on-year to ₹167 crore in Q1FY27.
EBITDA jumped 88% to ₹32.5 crore, with margins expanding to 19.5%.
Net profit rose 142% year-on-year to ₹16 crore.
The stock reached a new 52-week high of ₹1,713.70.
- Who
- Tatva Chintan Pharma Chem
- What
- Stock price surge due to strong Q1FY27 earnings
- When
- July 20, 2024
- Where
- Mumbai, India
- Why
- Strong revenue, EBITDA, and net profit growth
Investors
Market Analysts
Stock Performance
Investors
Investors are optimistic about the stock's performance and future growth potential.
Market Analysts
Analysts caution about the high valuation and potential market risks.
- Stock Price
- ₹1,685.10
- Revenue Growth
- 42% YoY
- EBITDA Growth
- 88% YoY
- Net Profit Growth
- 142% YoY
- Market Capitalization
- ₹3,940 crore
- P/E Ratio
- 93.72
- 52-Week Low
- ₹976.40
- 52-Week High
- ₹1,713.70